Syncytial Virus 1.


Hall CB, McCarthy CA, Respiratory syncytial virus. In: Mandell JL, Bennett JE, Dolin R, Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, Sixth edition, London, Churchill Livingstone, 2004;2009–21.


2.


Nair H, Nokes DJ, Gessner BD, et al., Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systemic review and meta-analysis, Lancet, 2010;375(9725):1545–55.


3.


Falsey AR, Walsh EE, Capellan J, et al., Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (RSV) vaccines — non-adjuvanted vaccine or vaccine adjuvanted with alum — given concomitantly with influenza vaccine to high-risk elderly individuals, J Infect Dis, 2008;198(9):1317–26.


4. Castilow EM, Olson MR, Varga SM, Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease, Immunol Res, 2007;39(1–3):225–39.


5. Peters TR, Crowe J, Respiratory syncytial virus. In Long SS, Pickering LK, Prober, CG, Principles and Practices of Pediatric Infectious Diseases, third edition, London, Saunders, 2009;1112–6.


6.


Murphy BR, Hall SL, Kulkarni AB, et al., An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza type 3 (PIV3) vaccines, Virus Res, 1994;32(1):13–36.


7. 8.


Ogra PL, Respiratory syncytial virus: the virus, the disease and the immune response, Paediatr Respir Rev, 2004;5(Suppl. A):S119–26.


Hall CB, Respiratory syncytial virus and parainfluenza virus, N Engl J Med, 2001;344(25):1917–28.


9. Sullender WM, Respiratory syncytial virus genetic and antigenic diversity, Clin Microbiol Rev, 2000;13(1):1–15.


10.


Hoffman SJ, Laham, FR, Polack FP, Mechanisms of illness during respiratory syncytial virus infection: the lungs, the virus, and the immune response, Microbes Infect, 2004;6(8):767–72.


11. 12.


Bueno SM, González PA, Pacheco R, et al., Host immunity during RSV pathogenesis, Int Immunopharmacol, 2008;8(10): 1320–9.


Culley FJ, Pennycook AM, Tregoning JS, et al., Differential chemokine expression following respiratory virus infection reflects Th1- or Th2-biased immunopathology, J Virol, 2006;80(9):4521–7.


13. 14.


Anderson LJ, Hellman CA, Protective and disease- enhancing immune responses to respiratory syncytial virus, J Infect Dis, 1995;171(1):1–7.


Oshansky CM, Zhang W, Moore E, Tripp RA, The host response and molecular pathogenesis associated with respiratory syncytial virus infection, Future Microbiol, 2009;4:279–97.


15. 16. 17. 18. 19.


Colllins PL, Graham BS, Viral and host factors in human respiratory syncytial virus pathogenesis, J Virol, 2008;82(5):2040–55.


Kneyber MC, Kimpen JL, Current concepts on active immunization against respiratory syncytial virus for infants and young children, Pediatr Infect Dis, 2002;21(7):685–96.


Polack FP, Karron RA, The future of respiratory syncytial virus vaccine development, Pediatr Infect Dis J, 2004;23 (Suppl. 1):S65–73.


Castilow EM, Varga SM, Overcoming T cell-mediated immunopathology to achieve safe RSV vaccination, Future Virol, 2008;3(5):445–54.


Johnson TR, Teng MN, Collins PL, Graham BS, Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV, J Virol, 2004;78(11):6024–32.


20.


Johnson TR, Graham BS, Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-independent mechanism, J Virol, 1999;73(10):8485–95.


21.


van Drunen Littel-van den Hurk S, Mapletoft JW, Arsic N, Kovacs-Nolan J, Immunopathology of RSV infection:


31. 32. 33. 34.


prospects for developing vaccines without this complication, Rev Med Virol, 2007;17(1):5–34.


22. 23. 24. 25.


Wang SZ, Harrod KS, The immunobiology of respiratory syncytial virus infection, Clin Appl Immunol Rev, 2006;6(1): 37–52.


Dodd JS et al., IL-19 regulates pathology during primary and memory responses to RSV infection, J Immunol, 2009;183:7006–13.


McNamara PS, Flanagan BF, Baldwin LM, et al., Interleukin 9 production in lungs of infants with severe respiratory syncytial virus bronchiolitis, Lancet, 2004;363(9414):1031–7.


Wilson J, Rowlands K, Rockett K, et al., Genetic variation at the IL10 gene locus is associated with severity of respiratory syncytial virus bronchiolitis, J Infect Dis, 2005;191(10):1705–9.


26.


Stevens WW, Sun K, Castillo JP, Braciale TJ, Pulmonary eosinophilia is attenuated by early responding CD8+ memory T cells in a murine model of RSV vaccine- enhanced disease, Viral Immunol, 2009;22(4):243–51.


27. 28. 29.


Peebles RS, Graham BS, Pathogenesis of respiratory syncytial virus infection in the murine model, Proc Am Thorac Soc, 2005;2(2):110–5.


Hou W, Kang HS, Kim BS, Th17 cells enhance viral persistence and inhibit T cell cytotoxicity in a model of chronic virus infection, J Exp Med, 2009;206(2):313–28.


Kim HW, Canchola JG, Brandt CD, et al., Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine, Am J Epidemiol, 1969;89(4):422–34.


30.


Olson MR, Varga SM, CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease, J Immunol, 2007;179:(8)5415–24.


Yoon JS, Kim HH, Lee Y, Lee JS, Cytokine induction by respiratory syncytial virus and adenovirus in bronchial epithelial cells, Pediatr Pulmonol, 2007;42(3):277–82.


Moghaddam A, Olszekska W, Wang B, et al., A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines, Nat Med, 2006;12(8):905–7.


Hussell T, Pennycock A, Openshaw PJ Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology, Eur J Immunol, 2001;31(9):2566–73.


Chin J, Magoffin RL, Shearer LA, et al., Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population, Am J Epidemiol, 1969;89(4):449–63.


35. 36. 37.


Harker J, Bukreyev A, Collins PL, et al., Virally delivered cytokines alter the immune response to future lung infections, J Virol, 2007;81(23):13105–11.


Crowe JE Jr, Influence of maternal antibodies on neonatal immunization against respiratory viruses, Clin Infect Dis, 2001;33(10):1720-7.


Shinoff JJ, O’Brien KL, Thumar B, et al., Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus, J Infect Dis, 2008;198(7):1007–15.


38. 39. 40. 41.


Kahn JS, Respiratory syncytial virus vaccine development, Curr Opin Pediatr, 2000;12(3):257–62.


Murata Y, Respiratory syncytial virus vaccine development. Clin Lab Med, 2009;29(4):725–39.


Schickli JH, Dubovsky F, Tang RS, Challenges in developing a pediatric RSV vaccine, Hum Vaccin, 2009;5(9):582–91.


Meyer G, Deplanche M, Schelcher F, Human and bovine respiratory syncytial virus vaccine research and development, Comp Immunol Microbiol Infect Dis, 2008;31(2–3): 191–225.


42.


A randomized, double-blind, placebo-dontrolled study to evaluate viral shedding of MEDI-559 in healthy 1 to <24 month-old children. Available at: http://clinicaltrials.gov/ ct2/show/NCT00767416 (accessed November 27, 2010).


43.


Karron RA, Wright PF, Belshe RB, et al., Identification of a recombinant live attenuated respiratory virus vaccine candidate that is highly attenuated in infants, J Infect Dis,


58. 59. 55. 53. 50. 46. 2005;191(7):1094–104. 44. 45.


Empey KM, Peebles RS Jr, Kolls JK, Pharmacologic advances in the treatment and prevention of respiratory syncytial virus, Clin Infect Dis, 2010;50(9):1258–67.


Simoes EA, Tan DH, Ohlsson A, et al., Respiratory syncytial virus vaccine: a systematic overview with emphasis on respiratory syncytial virus subunit vaccines, Vaccine, 2001;20(5–6):954–60.


Munoz FM, Piedra PA, Glezen WP, Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women, Vaccine, 2003;21(24):3465–7.


47.


de Waal L, Power UF, Yüksel S, et al., Evaluation of BBG2Na in infant macaques: specific immune responses after vaccination and RSV challenge, Vaccine, 2004;25(8):915–22.


48.


Kim S, Jang JE, Yu JR, Chang J, Single mucosal immunization of recombinant adenovirus-based vaccine expressing F1 protein fragment induces protective mucosal immunity against respiratory syncytial virus infection, Vaccine, 2010;28(22):3801–8.


49.


Martinez-Sobrido L, Gitiban N, Fernandez-Sesma A, et al., Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector, J Virol, 2006;80(3):1130–9.


Slobod KS, Shenep JL, Luján-Zilbermann J, et al., Safety and immunogenicity of intranasal murine parainfluenza virus type I (Sendai virus) in healthy human adults, Vaccine, 2004;22(23–24):3182–6.


51.


Murawski MR, McGinnes LW, Finberg RW, et al., Newcastle disease virus-like particle containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology, J Virol, 2010;84(2): 1110–23.


52.


Zhan, X, Hurwitz JL, Krishnamurthy S, et al., Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B, Vaccine, 2007;25(52):8782–93.


Gomez M, Mufson M, Dubovsky F, et al., Phase-I Study MEDI-534 of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 in seropositive children, Pediatr Infect Dis J, 2009;28(7);655–8.


54.


Tang RS, MacPhail M, Schickli JH, et al., Parainfluenza virus type 3 expressing the native or soluble fusion (F) protein of respiratory syncytial virus confers protection from RSV infection in African green monkeys, J Virol, 2004;78(20):11198–297.


Tang RS, Spaete RR, Thompson MW, et al., Development of a PIV-vectored RSV vaccine: preclincial evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults, Vaccine, 2008 26(50);6373–82.


56.


Hurwitz JL, Development of recombinant Sendai virus vaccines for prevention of human parainfluenza and respiratory syncytial virus infections, Pediatr Inf Dis J, 2008;27(Suppl. 10):S126–8.


57.


Widjojoatmodjo MN, Boes J, van Bers M, et al. A highly attenuated recombinant human respiratory syncytial virus lacking the G protein induces long-lasting protection in cotton rats, Virol J, 2010;7:114.


Piedra P, Clinical experience with respiratory syncytial virus vaccines, Pediatr Inf Dis J, 2003;22(2 Suppl):S94–9.


Wright PF, Karron RA, Belshe RB, et al., Evaluation of a live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccine candidate in infancy, J Inf Dis, 2000;182(5):1331–42.


60. 61.


Power UF, Respiratory syncytial virus (RSV) vaccines— two steps back for one leap forward, J Clin Virol, 2008;41(1):38–44.


McNamara PS, Flanagan BF, Selby AM, et al., Pro- and anti-inflammatory responses in respiratory syncytial virus bronchiolitis, Eur Respir J, 2004;23(1):106–12.


64


US RESPIRATORY DISEASE


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84